Effects of Allulose and Aspartame Intake on Postprandial Glucagon-Like Peptide-1 Profiles and Metabolic Indicators

A sweetener that talks to the gut

Allulose already has a solid pitch for formulators: 0.2–0.4 kcal/g, real browning, real texture, real volume. The missing piece is what it does inside the gut. A new clinical study aims to fill that gap.

The paper, DOI 10.2196/81857, outlines an acute head-to-head trial. Healthy adults consume allulose or aspartame. The primary endpoint is the postprandial glucagon-like peptide 1 (GLP-1) profile. GLP-1 drives satiety, slows gastric emptying, and supports insulin release. If allulose moves that curve, its role in food products changes.

Why GLP-1 matters to formulators

GLP-1 is one of the hottest targets in metabolic health. Drug companies built major therapies around it. Food ingredients that influence it naturally are rare. Aspartame sits on the other side of the comparison. It's the reference point, not the protagonist. The study asks a direct question: does allulose trigger a different GLP-1 response than aspartame? The answer could separate allulose from every other sweetener on your bench.

What the study actually did

Healthy adults received either allulose or aspartame, and researchers mapped the postprandial GLP-1 response. That's the core comparison. The protocol also tracks gut microbiome composition, short-chain fatty acids, and insulin sensitivity. These endpoints make the study more than a sweetener test. They connect GLP-1 changes to metabolism and gut health.

Allulose's known profile fits the study's logic. It provides bulk, browning, and texture with negligible energy. If it also stimulates GLP-1, formulators have a sweetener that does two jobs at once.

Comparison point	Allulose	Aspartame
Energy contribution	0.2–0.4 kcal/g	Not specified in the abstract
Functional properties	Browning, texture, volume filling	Not specified in the abstract
Postprandial GLP-1 measured	Yes	Yes
Gut microbiome, SCFAs, insulin sensitivity measured	Yes	Yes

The table separates what's confirmed from what's being tested. Allulose's physical functionality is established. Its GLP-1 effect is the open question.

What this means for manufacturers

If the data favors allulose, the ingredient's value shifts. You stop selling a sugar replacement. You start selling a functional sugar alternative with metabolic relevance. That opens formulation space in satiety-oriented products, diabetic-friendly foods, and reduced-sugar lines with benefits.

Don't overread the abstract. This is an acute exposure protocol, not a long-term feeding study. Dose, timing, and subject population all factor into the final interpretation. Wait for the complete report. Then replicate with your own prototype.

The gut microbiome and SCFA data deserve attention too. If allulose shifts microbial composition, that creates a separate digestive-health narrative for bulk buyers. Watch those secondary endpoints closely.

FAQ

Does allulose have calories? Yes, but very few. It provides 0.2–0.4 kcal/g, a fraction of sugar's energy.

Will this study support a GLP-1 claim on my label? Unlikely, at least not immediately. This is one acute trial. Regulatory claims require more evidence and a formal framework.

How do the doses compare? The abstract doesn't disclose them. That detail will be essential when full results appear.

The next step

Read the protocol. Track the outcomes. If allulose beats aspartame on GLP-1, you'll want application data before competitors do. If it doesn't, allulose still holds its low-calorie, sugar-like functionality. Either way, this study sharpens the question every formulator should ask: what is my sweetener doing beyond sweetness?